Literature DB >> 10499244

Management of breakthrough pain due to cancer.

M A Simmonds1.   

Abstract

Breakthrough pain is defined as the transient exacerbation of pain occurring in a patient with otherwise stable, persistent pain. Breakthrough pain is relatively common among cancer patients, particularly those with moderate to severe background pain, and is one of the most difficult pain syndromes to treat. Breakthrough pain may be caused by patient movement (incident pain) or may be unrelated to patient action (spontaneous pain). Although breakthrough pain is usually managed pharmacologically with supplemental opioid medication, other means of treatment should also be considered. Primary antineoplastic therapies may alleviate the cause of some breakthrough pain, and other types of primary interventions may at least lessen this type of pain. Before a change in the around-the-clock analgesic dosage is implemented, the clinician should consider analgesic side effects, the number of episodes of breakthrough pain per day, and the best means for balancing side effects vs analgesia. The addition of pharmacologic agents to treat analgesic side effects may improve the overall side effect profile. Because breakthrough pain involves moderate to severe pain of rapid onset, use of a fast-acting, effective analgesic can be crucial to successful treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499244

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  7 in total

Review 1.  Breakthrough pain in cancer patients: new therapeutic approaches to an old challenge.

Authors:  S K Reddy; P Nguyen
Journal:  Curr Rev Pain       Date:  2000

2.  [Experiences of cancer patients with breakthrough pain and pharmacological treatments].

Authors:  L Bertram; S Stiel; F Elsner; L Radbruch; A Davies; F Nauck; B Alt-Epping
Journal:  Schmerz       Date:  2010-12       Impact factor: 1.107

3.  Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial.

Authors:  Naohito Shimoyama; Ikuo Gomyo; Nobuyuki Katakami; Masakuni Okada; Nobuyuki Yukitoshi; Eri Ohta; Megumi Shimoyama
Journal:  Int J Clin Oncol       Date:  2014-05-20       Impact factor: 3.402

4.  A new transmucosal drug delivery system for patients with breakthrough cancer pain: the fentanyl effervescent buccal tablet.

Authors:  Enno Freye
Journal:  J Pain Res       Date:  2008-12-17       Impact factor: 3.133

Review 5.  What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion.

Authors:  R Vellucci; G Fanelli; R Pannuti; C Peruselli; S Adamo; G Alongi; F Amato; L Consoletti; L Lamarca; S Liguori; C Lo Presti; A Maione; S Mameli; F Marinangeli; S Marulli; V Minotti; D Miotti; L Montanari; G Moruzzi; S Palermo; M Parolini; P Poli; W Tirelli; A Valle; P Romualdi
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

Review 6.  Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology.

Authors:  Kyriaki Mystakidou; Eleni Tsilika; Marinos Tsiatas; Lambros Vlahos
Journal:  Int J Nanomedicine       Date:  2007

7.  A protocol for a systematic review and meta-analysis to identify measures of breakthrough pain and evaluate their psychometric properties.

Authors:  Katie Greenfield; Simone Holley; Daniel Eric Schoth; Julie Bayliss; Anna-Karenia Anderson; Satbir Jassal; Dilini Rajapakse; Lorna Katharine Fraser; Christine Mott; Margaret Johnson; Ian Wong; Richard Howard; Emily Harrop; Christina Liossi
Journal:  BMJ Open       Date:  2020-03-29       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.